What are the limits in the fight against obesity? Ozempic owner disappoints the marketNovo Nordisk faces challenges in sustaining growth with competition in obesity treatments, particularly after CagriSema's trial results.
Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelmsCagriSema failed to meet weight loss expectations in trials, causing significant stock decline for Novo Nordisk.
What are the limits in the fight against obesity? Ozempic owner disappoints the marketNovo Nordisk faces challenges in sustaining growth with competition in obesity treatments, particularly after CagriSema's trial results.
Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelmsCagriSema failed to meet weight loss expectations in trials, causing significant stock decline for Novo Nordisk.